Extension Phase of a Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia.
Wang J, Fabi S, Robinson D, Bajaj S, Geronemus R, Bell M, Robison T, Widgerow A. Extension Phase of a Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia. Journal Of Drugs In Dermatology 2023, 23: 1266-1270. PMID: 38206144, DOI: 10.36849/jdd.7622.Peer-Reviewed Original ResearchConceptsFacial dyschromiaMulti-center trialClinical studiesBlinded clinical studyTopical productsALS cohortExtension studyHydroquinone 4%Follow-up visitExtension phaseClearance of pigmentAssociated with increased productionMulti-centerDaily sunscreen useReduced clearanceCohortDyschromiaSunscreen useIn vitroWeeksTrialsLong-term basisSignificant reboundSkinEfficacyA Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia.
Wang J, Fabi S, Robinson D, Bajaj S, Geronemus R, Bell M, Widgerow A. A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia. Journal Of Drugs In Dermatology 2023, 22: 333-338. PMID: 37026875, DOI: 10.36849/jdd.7340.Peer-Reviewed Original ResearchConceptsModified Melasma Area Severity IndexHydroquinone 4%Post-inflammatory hyperpigmentationFacial dyschromiaBlinded clinical studyFollow-upClinical studiesTopical productsAdverse eventsModified melasma area severity index scoreMulti-centerMelasma Area Severity IndexArea Severity IndexNo adverse eventsClearance of pigmentIn vitro studiesExcessive sun exposureBlinded investigatorRight cheekWeek 4Griffiths ScalesReduced clearanceSun exposureMedical disordersTolerability assessments